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Comparative membrane proteomics: a technical
advancement in the search of renal cell
carcinoma biomarkers†
Francesca Raimondo,*a Samuele Corbetta,a Andrea Savoia,a Clizia Chinello,a
Marta Cazzaniga,a Francesco Rocco,b Silvano Bosari,c Marco Grasso,d
Giorgio Bovo,d Fulvio Magnia and Marina Pittoa
Renal Cell Carcinoma (RCC) is the most common kidney cancer, accounting for 3% of adult malignancies,
with high metastatic potential and radio-/chemo-resistance. To investigate the protein profile of membrane
microdomains (MD), plasma membrane supramolecular structures involved in cell signaling, transport,
and neoplastic transformation, we set up a proteomic bottom-up approach as a starting point for the
identification of potential RCC biomarkers. We purified MD from RCC and adjacent normal kidney (ANK)
tissues, through their resistance to non-ionic detergents followed by ultracentrifugation in sucrose density
gradient. MD from 5 RCC/ANK tissues were then pooled and analysed by LC-ESI-MS/MS. In order to identify
the highest number of proteins and increase the amount of membrane and hydrophobic ones, we first
optimized an enzymatic digestion protocol based on Filter Aided Sample Preparation (FASP), coupled to MD
delipidation. The MS analysis led to the identification of 742 ANK MD and 721 RCC MD proteins, of which,
respectively, 53.1% and 52.6% were membrane- bound. Additionally, we evaluated RCC MD diﬀerential
proteome by label-free quantification; 170 and 126 proteins were found to be, respectively, up-regulated
and down-regulated in RCC MD. Some diﬀerential proteins, namely CA2, CD13, and ANXA2, were
subjected to validation by immunodecoration. These results show the importance of setting up diﬀerent
protocols for the proteomic analysis of membrane proteins, specific to the diﬀerent molecular features
of the samples. Furthermore, the subcellular proteomic approach provided a list of diﬀerentially
expressed proteins among which RCC biomarkers may be looked for.
Introduction
Renal Cell Carcinoma (RCC) is the deadliest tumor of the
genitourinary tract. Clear cell renal cell carcinoma represents the
most common histotype, accounting for 70–80% of all kidney
cancers. Due to its asymptomatic development, approximately
80%of RCCs are discovered incidentally during unrelated diagnostic
abdominal imaging, when the disease is already in the advanced
phase.1,2 Furthermore, RCC is chemotherapy and immunotherapy
resistant, and nephrectomy is the only beneficial therapy.
Once metastases develop, the prognosis for long-term survival
is poor; the 5 year survival rate for non-treated patients is usually
less than 14%. Nevertheless, there are currently no circulating
validated biomarkers able to confirm the identity of renal
masses, whether benign or malignant.3,4
Plasma membrane proteomics seems to be a promising tool
to address this issue, as membrane proteins perform endocy-
tosis and signaling, and modifications of plasma membrane
composition are encountered in several cancers.5,6 Moreover,
about two-thirds of membrane proteins are drug targets, hence
crucial for therapy advancement.
In particular, within the membrane, there are specialized
microdomains, also known as lipid rafts. Membrane micro-
domains (MD) are small (10–200 nm), heterogeneous, highly
dynamic, sterol- and sphingolipid-enriched lateral assemblies
that compartmentalize cellular processes. Caveolae, a subclass of
such MD, are flask-like invaginations of the plasma membrane
that characteristically display caveolin-1 expression.7
MD are highly dynamic structures and act as selective signal
transduction mediators, enabling interactions between the
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intra- and extra-cellular compartments. Furthermore, they play
a key role in drug resistance, cell migration, cell adhesion, and
cell survival, as well as in metastasis and tumor progression.8–11
Since membrane microdomains represent a minor and highly
selected subset of the cellular proteome, they are particularly
well suited to investigation using MS techniques. However,
their peculiar lipid composition and the enrichment in highly
hydrophobic membrane proteins make the assessment of the
microdomain proteome a hard issue to address, therefore requiring
the optimization of specific protocols. In fact, membrane proteins
are usually under-represented in classical proteomic approaches
relying on 2D gel electrophoresis (2DE) andMS analysis. This is due
to them being generally not very abundant, their isoelectric points
(pIs) being generally alkaline and their solubility in the aqueous
buffers used for isoelectrofocusing (IEF) being poor.11–13 Recent
data on the quantitative proteomics of MD – lipid rafts or caveolae –
have underlined the puzzling role of various signaling proteins in
cancer development, but these studies were mainly performed on
neoplastic cell lines.14–17 However, procedures commonly used for
cell cultures, such as metabolic labelling, are not suitable for the
study of human tissue MD, making label-free quantification a
valid choice to achieve differential expression profiles. Moreover,
the protocol needs to be adapted to small amount of samples, as
feasible when working with human surgical specimens.
For these reasons, starting from human surgical samples, we
focused on the pre-analytical phase of sample preparation, in order
to improve the identification ofMDmembrane proteins, using a gel-
free approach through liquid chromatography coupled to tandem
mass spectrometry (LC-MS/MS). We evaluated three diﬀerent
digestion protocols based on the Filter Aided Sample Preparation
(FASP) technique, and, after optimization, we assessed diﬀerential
RCC MD proteomes by label-free quantification, as a starting
point for the identification of potential RCC biomarkers.
Materials and methods
Chemicals
Solutions were prepared with Milli-Q water. Water of HPLC grade,
trifluoroacetic acid (TFA), isopropyl alcohol, tributyl phosphate
(TBP), ammonium bicarbonate (ABC), dithiothreitol (DTT), iodo-
acetamide (IAA), urea, Triton X-100, Tween-20, Trizma-base, MES,
sucrose, BCA protein assay reagent and BSA were from SIGMA
Chemical Co. (St. Louis, MO, USA). Acetonitrile (ACN), methanol,
and glycerol were from Merck (Darmstadt, Germany). Porcine
trypsin was from Promega (Madison, WI, USA). Bradford protein-
binding colorimetric assay was purchased from Bio-Rad (Hercules,
CA, USA). Anti-protease inhibitor cocktail (Complete) was from
Roche (Monza, Italy). NuPAGEs SDS-PAGE gel electrophoresis sys-
tem components (mini gels, running and loading buﬀers, molecular
weight markers and Coomassie brilliant blue staining–CBB)
were supplied by Life Technologies (Paisley, Renfrewshire, UK).
Hybond-ECL nitrocellulose membrane was from GE (Little Chalfont,
Buckinghamshire, UK). Anti-aminopeptidase N (CD13) monoclonal
antibody, anti-annexin A2 (ANXA2) and anti-carbonic anhydrase
(CA2) polyclonal antibodies were from Abcam (Cambridge, UK).
Species-specific secondary peroxidase conjugated antibodies
and ECL reagents were from Pierce (Rockford, IL, USA).
Patients and specimens
Patients with suspected RCC, not receiving any previous chemo-
therapy, were subjected to radical nephrectomy, after their
informed consent and the local research ethics committee approval
(U.O. Comitato di Etica e Sperimentazione Farmaci Direzione
Scientifica Fondazione IRCCS Ca’Granda Ospedale Maggiore
Policlinico, Milano). RCC was classified according to the WHO
recommendations18 and the 2009 TNM (tumor-node-metastasis)
system classification also using immunohistochemical techniques;
only samples diagnosed as conventional clear cell RCC were
included in the study. Tumor grading was performed according
to the Fuhrman grading system.19
Immediately after removal, the pathologist collected samples
of primary RCC, selected inside homogeneous areas and avoiding
grossly necrotic or fibrotic parts, and of homologous normal
cortical tissue (adjacent normal kidney, ANK) contiguous to the
tumoral mass. A minimum of one cm3 of tumor and normal cortex
were placed in sucrose buﬀered solution (250 mM sucrose, 10 mM
Tris-HCl, pH 7.4, 1 mM EDTA), kept on ice and immediately
transferred to the laboratory.
The clinical and personal features of the studied patients are
summarized in Table 1. Their neoplasms had quite homogeneous
characteristics, being in the early phase, and neither metastasis
nor positive lymph nodes were present at diagnosis.
Subcellular fractionation and microdomain isolation
After nephrectomy, fresh RCC and ANK tissue samples were
submitted to subcellular fractionation through diﬀerential
Table 1 Clear cell renal cell carcinoma samples analyzed in this study and
the corresponding clinical data
Patients Age Sex pT G
Membrane microdomains
ANK ANK vs. RCC
FASP set-upa FASPb 1DEc
45DM 53 F 1b 2 X X
46SA 67 F 2 2 X
47CA 78 F 1a 2 X
48GA 54 M 1b 2 X X
49CA 70 M 3b 3 X X
50PC 51 M 1b 2
51MI 61 F 1b 2 X X
52CA 59 F 2a 2 X
60CC 78 M 3a 3 X X
61FG 56 M 1b 2 X X
66SML 48 F 2a 2 X
70LS 71 M 1b 2 X
72FG 59 M 1a 2 X
75CPL 71 M 1b 2 X
77FG 70 M 1b 2 X
80MLA 78 F 3b 2–3 X
91BE 58 M 3b 1 X
117VLF 43 M 2 2 X
pT, tumor stage; G, nuclear grade. a Samples used for the preparation of
the ANK MD pool in order to optimize the FASP protocol. b Samples
used for the label-free quantitation. c Samples analyzed by 1DE.20
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centrifugation; all steps were performed in a cold room (4 1C) or
on ice. Subcellular and microdomain-enriched fractions were
isolated and characterized as described.20
Electrophoresis and western blotting
Protein separation was performed by the NuPAGEs electro-
phoresis system (Life Technologies). Equal amounts (10 mg) of
subcellular fraction proteins were separated by 4–12% NuPAGE
and blotted onto nitrocellulose membranes using a mini tank
electrophoretic transfer apparatus (Hoefer). Membranes were
developed with the respective primary antibodies (anti-CD13 1 :2000,
anti-ANXA2 1 :2000, and anti-CA2 1 :1000), followed by peroxidase-
conjugated secondary antibodies (Pierce) and enhanced chemi-
luminescence detection (SuperSignal West-Pico ECL, Pierce). Images
were captured on a CCD camera, LAS4000 (GE Healthcare).
Delipidation and protein precipitation by tri-n-butylphosphate/
acetone/methanol
Aliquots (100 mL) of the MD pools were mixed with 14 volumes of
ice-cold TBP/acetone/methanol mixture (1 : 12 : 1) and incubated
at 4 1C for 90 minutes. Proteins were precipitated by centrifuga-
tion at 2800  g for 15 minutes (4 1C), washed sequentially with
1 mL of TBP, acetone and methanol, and then air-dried.21 During
the set-up of delipidation experiments, we assessed a loss of MD
proteins of about 20%. Accordingly, we performed delipidation on
150 mg of ANK and RCCMD, since 100 mg of proteins were required
for FASP protocols. In order to evaluate the reproducibility of protein
extraction, we performed quantitative protein assay using the
BCA reagent on delipidated samples and verified the recovery
after NuPAGE/CBB staining, by loading equal aliquots of ANK
and RCC MD delipidated samples.
Filter aided sample preparation: protocol optimization
Due to the peculiar MD lipid composition, we optimized an
enzymatic digestion protocol based on Filter Aided Sample
Preparation (FASP),22 comparing three diﬀerent protocols
(Table 2), with and without previous delipidation. For this
purpose, equal amounts of MD isolated from ANK tissues of
11 patients (Table 1) were pooled in order to eliminate inter-
individual diﬀerences.
Protocol 1 was an adapted version of the FASP digestion by
Wis´niewski et al.,22 already reported for the MS analysis of
urinary exosomes.23 The lysis of MD, about 100 mg of proteins,
was performed by a 30 min incubation in RIPA buﬀer (50 mM
Tris-HCl pH 7.4, 1% NP40, 0.25% sodium deoxycholate, 150 mM
NaCl, and 1 mM EDTA). MD were then submitted to disulfide
bond reduction with 50 mM DTT in 50 mM ABC (95 1C for
5 min). After cooling the sample, the lysates were transferred
into the ultrafiltration units (Amicon Ultra-0.5 mL 30 kDa,
Millipore) and centrifuged at 14000  g for 15 min in order to
eliminate lysis buﬀer and DTT. The filters were washed with
300 mL of 50 mM ABC (14000  g for 10 min) and the samples
were incubated with 80 mL of 100 mM IAA in darkness for
30 min. IAA was discharged by centrifugation at 14000  g for
5 min, and the filters were washed with 200 mL of 50 mM ABC five
times (14000  g for 10 min). Proteins were digested overnight at
37 1C by 4 mg of trypsin for each sample. After digestion, the
filtered tryptic peptides were collected by centrifugation with two
washes of water (40 mL and subsequently 100 mL).
In protocol 2, lysis and reduction steps were the same as
protocol 1; alkylation was performed by incubating the samples
with 100 mL of 50 mM IAA in darkness for 20 min. After IAA
elimination, the filters were washed with 100 mL of 50 mM
ABC four times (14 000  g for 15 min). Protein digestion was
performed overnight at 37 1C adding 1 mg of trypsin. After
centrifugation at 14 000  g for 10 min, the filtered tryptic
peptides were collected, and the filters washed with 50 mM ABC
and 500 mM NaCl, two times each. The eluted peptides were
acidified by 0.1% TFA.
In protocol 3, the sample was solubilized by a denaturation
buﬀer containing SDS and DTT (2% SDS, 50 mM DTT, 50 mM
Tris-HCl pH 7.6), incubated at 95 1C for 5 minutes. Dissolved
MD membranes (70 mL) were mixed with 430 mL of 8 M urea in
100 mM Tris-HCl, pH 8.5 (UA 8.5 solution), transferred into the
ultrafiltration device and centrifuged at 14000  g for 15 minutes.
Alkylation was performed as in protocol 2, followed by four washes,
two with 8 M urea in 100 mM Tris-HCl, pH 7.9 (UA 7.9 solution)
and two with 50mMABC (14000 g for 15min). Protein digestion
and peptide elution were the same as protocol 2.
Digestion and peptide extraction
MD isolated from RCC and ANK tissues of 5 patients were
pooled (Table 1), and the resulting samples were lysed and
subjected to protein extraction and digestion by the FASP
protocol 3, after delipidation.
MD proteome analysis by nLC-ESI-MS/MS
All the MS analysis and protein identification were performed
under the same conditions. Before LC-MS analysis, tryptic digests
for each sample were quantitated using a NanoDrop spectro-
photometer and desalted using Ziptipt m-C18 (Millipore) following
manufacturer’s instructions.24 About 1 mg of digested proteins for
each sample run were injected at least 3 times into a Dionex
UltiMate 3000 rapid separation (RS) LC nanosystem (Thermo
Scientific, Germany) coupled online with a nano ESI ion trap
mass spectrometer, amaZon ETD (Bruker Daltonics GmbH,
Germany). After the m-trapping column desalting (Dionex,
Acclaim PepMap 100 C18, cartridge, 300 mm ID  5 mm,
5 mm) and concentration steps, peptides were then separated
Table 2 FASP protocolsa
FASP
protocol
Denaturation
buﬀer
DTT
(mM)
IAA
(M)
Washing
buﬀer
Trypsin
digestion
(mg) Elution
1 RIPA 50 0.1 ABC 4 H2O
2 RIPA 50 0.05 ABC 1 NaCl 0.5 M
TFA 0.1%
3 SDS 50 0.05 UA 1 NaCl 0.5 M
TFA 0.1%
a ABC, 50 mM ammonium bicarbonate buﬀer; UA, 8 M urea in 100 mM
Tris-HCl pH 8.5 and 8 M urea in 100 mM Tris-HCl pH 7.9; TFA,
trifluoroacetic acid.
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by a 360 min-multistep gradient on the analytical 50 cm nano-
column (Dionex, 0.075 mm ID, Acclaim PepMap100, C18, 2 mm)
with a flow rate of 300 nl min1 as already described.25 The ion-
trap mass spectrometer equipped with an on-line nanospray
source was operated in data-dependent-acquisition mode. For
MS generation, enhanced resolution and a trap ICC value of
400 000 were used; for MS/MS acquisition, the ICC target was
increased to 1 000 000; a narrow range for Smart Fragmentation
from 50 to 150%was adopted. CIDMS/MS fragmentation was set
to fragment the ten most abundant MS peaks with strictly active
exclusion after one spectrum and released after 9 seconds.
The obtained chromatograms were elaborated using Compass
DataAnalysisTM, v.4.0 Sp4 (Bruker Daltonics, Germany), and the
resulting mass lists were processed using an in-house Mascot
search engine (v.2.4.0), through Mascot Daemon. Database
searching was restricted to the human Swissprot database
(accessed Apr 2014; 544996 sequences; 193 815432 residues).
Trypsin as an enzyme and carbamidomethyl (C) as a fixedmodifica-
tion were set in search parameters. Mass tolerance for all identifica-
tions was generally fixed at 2 Da for the precursor ions and 0.8 Da
for the product ions. Automatic decoy database search and a built-in
Percolator algorithm were applied to calculate the posterior error
probabilities for each peptide-spectrummatch and rescore search
results with a unique significance threshold. Data were filtered
using a global false discovery rateo 1% and only proteins with at
least one unique identical peptide sequence (p-valueo 0.05) were
considered identified.26
Label-free protein abundance evaluation
Protein abundance in MD of RCC and ANK tissues was deter-
mined using Progenesis LC-MS software v 4.1 (Non-linear
Dynamics, Newcastle, England). The raw LC-MS/MS data were
imported and the ion intensity maps of all runs (3 runs for each
class) were visually examined for defects and used for the
alignment process, performed using the ‘‘Automatic Alignment’’
function. One sample is thus set as the reference run and the
retention times of all other samples within the experiment were
automatically aligned to create a maximal overlay across the
data. The default sensitivity and a peak width of 0.2 min were
selected as parameters for the feature detection algorithm.
Samples were then allocated to their experimental class (RCC
vs. ANK). The identification of peptides was performed using an
in-house Mascot search engine as described above. The filtered
MASCOT search results were imported back into Progenesis
LC-MS and the identified peptides with a score lower than 13
were discarded (p-value4 0.05). Experimental variation aﬀecting
the protein expression was minimized by analyzing the same
amount of sample (1 mg) and by the normalization process
performed using Progenesis software (http://www.nonlinear.
com/progenesis/qi-for-proteomics/v2.0). Protein quantification
results were exported and used for further analysis.
Bioinformatic analysis
Gene ontology (GO) analysis was performed using the LocDB
database (www.rostlab.org/services/locDB/) for investigating
the subcellular localization of the identified proteins and the
Protein ANalysis THrough Evolutionary Relationship (PANTHER)
database (http://www.pantherdb.org/) for the analysis of their
molecular functions. In addition, membrane proteins were
deeply studied and transmembrane helix prediction was per-
formed using the online TMHMM 2.0 prediction server (http://
www.cbs.dtu.dk/services/TMHMM/),27,28 palmitoylation was pre-
dicted using CSS-Palm 2.0,29 GPI-modification site prediction
was conducted through the online big-PI predictor server (http://
mendel.imp.ac.at/sat/gpi/gpi_server.html)30 and myristoylation
was predicted using the online Expasy Myristoylator prediction
server (http://web.expasy.org/myristoylator/).31 Protein–protein
interactions were predicted using the Search Tool for the Retrieval
of Interacting Genes/Proteins (STRING) database v9.0 (http://www.
string-db.org/) and proteins were linked based on the following six
criteria: neighbourhood, gene fusion, co-occurrence, co-expression,
experimental evidence and existing databases.32
Tissue specificity of the identified proteins was evaluated
using diﬀerent databases available in the Human Protein Atlas
(HPA) (http://www.proteinatlas.org/).33 In particular, MD proteins
were compared with: (i) the human specific proteome of 32
tissues, summing up ‘‘tissue enriched’’, ‘‘group enriched’’ and
‘‘tissue enhanced’’ gene categories; (ii) the housekeeping pro-
teome (proteins detected in all tissues); and (iii) the renal
cancer proteome, considering only the proteins detected in at
least 80% of the HPA analysed patient tissues.
Results and discussion
Protocol setup
For the optimization of the digestion protocol, we pooled MD
isolated from ANK tissues of 11 patients in order to eliminate
inter-individual diﬀerences. Then we subjected aliquots of
100 mg of proteins to the three protocols, and analyzed them
by LC-MS/MS.
In order to select the best protocol, we took into considera-
tion: (i) the number of total proteins identified by the Mascot
search engine; (ii) the amount of hydrophobic proteins on
the basis of the hydrophobicity score, GRAVY index (assigned
by ProtParam http://web.expasy.org/protparam/); and (iii) the
percentage of membrane proteins (classification assigned by
LocDB and confirmed by TMHMM 2.0).
We first tested an adapted version of FASP digestion, already
used for the MS analysis of membrane proteins (hereafter named
‘‘Protocol 1’’) (Table 2).23 FASP is a method that combines strong
detergents for universal solubilization with eﬃcient pre-digestion
‘clean up’ of the proteome in order to obtain purified peptides,
avoiding the disadvantages of the gel format.22 The main feature of
Protocol 1 is the lysis of MD, performed by a 30 min incubation in
lysis RIPA buﬀer. The resulting analysis with LC-MS/MS led to
the identification of only 32 proteins with a few signals of low
intensity shown by the base peak chromatogram (ESI,† Fig. S1).
Due to the peculiar lipid composition of MD, we introduced
a step of protein delipidation and precipitation with tri-n-butyl-
phosphate, acetone, and methanol.21 This pretreatment ensured
the highest protein recovery, according to Shevchenko and
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colleagues.34 Using delipidation followed by Protocol 1, 103
proteins were identified (Fig. 1), a number still lower than in
our previous study (286 proteins).23 We then tested another
protocol (Protocol 2), by adding NaCl washing, in order to increase
the recovery of hydrophobic peptides, and one acidification
step with 0.1% TFA, on both delipidated and non-delipidated
samples (Table 2). These settings determined an increased, yet
not fully satisfactory, recovery of proteins (Fig. 1).
The conditions were then further modified in Protocol 3,
which, unlike the other protocols, involves the use of SDS buﬀer
and urea (Table 2). In particular, we performed all washings
with 8 M urea, which should fully wash out detergents from
membrane proteins.35 When applied without delipidation, this
protocol led to the identification of 170 proteins, of which only
23% were transmembrane proteins (Fig. 1). This could be due
to the lipids-SDS interaction: as a consequence, the SDS cannot be
eﬃciently removed by the filter, interfering with the MS analysis
(ESI,† Fig. S1). Moreover, the filter may retain some lipid
components, together with hydrophobic lipid-bound proteins.
Conversely, Protocol 3 coupled to delipidation was the most
eﬃcient way to identify proteins in MD. In fact, firstly, the introduc-
tion of the delipidation step resulted in a significant increase in the
yield of total protein identification (N = 342). Secondly, the total
number of membrane proteins greatly increased (N = 222), boosting
the percentage of transmembrane proteins to 50%.
These results may depend on the depletion of the lipid
components, which likely enables the ‘‘release’’ of transmembrane
proteins. Once freed, they become more suitable for tryptic
digestion, thus generating peptides that can be eluted through
a 30-kDa cut-oﬀ FASP filter.36
LC-MS protein identification and label-free quantification
The optimized protocol was implemented to perform the
comparison between RCC and ANK MD. In fact, we speculated
that the delipidation step could eliminate some diﬀerences in
protein identification due to the diﬀerent lipid composition
(data not shown), making the comparative proteomic analysis
more reliable. We first evaluated the recovery after MD delipi-
dation as shown in the ESI,† Fig. S2. The extraction of ANK and
RCC MD proteins after delipidation is reproducible, and the
protein profiles were comparable with the non-delipidated ones
(ESI,† Fig. S2). Proteins of microdomain-enriched fractions
prepared from 5 paired samples of RCC and ANK tissues were
pooled and analyzed. Identification was accepted with at least
one unique peptide exceeding the Mascot score of identity cut-
oﬀ, in order to ensure a better understanding of MD proteomes.
Exploiting the powerful peak detection of the Progenesis algorithm
(used during the label-free protein expression evaluation), and
applying the above detailed criteria, MS/MS analysis after FASP
digestion led to the identification of 742 proteins in ANK and
721 in ccRCC MD. Overall, more than 800 protein species were
identified; their full details, including scores and the number
of matched peptides, are given in the ESI,† Tables S1 and S2.
The molecular characteristics of the identified proteins were
assessed by bioinformatics and prediction tools.37 The results
showed that the majority of the identified proteins (53.1% and
52.6% in ANK and RCC, respectively) were membrane-associated,
with about 58% of them being transmembrane proteins (ESI,†
Tables S1 and S2). Many of them were typical raft proteins, such
as caveolins (1 and 2), flotillins, aquaporin-1, prohibitins, VDAC1
and Thy-1. Comparing our list of total MD identified proteins to
RaftProt, a recently published Mammalian Lipid raft Proteome
Database (http://lipid-raft-database.di.uq.edu.au/index.html),38
580 (72%) were classified as human lipid raft associated
proteins and 394 (49%) as High Confidence lipid raft proteins.
Moreover, we investigated whether protein sequences contained
sites for post-translational modifications such as glypiation,
palmitoylation, and myristoylation, using prediction algorithms.
They assigned putative myristoylation sites to about 15% of
total identified membrane proteins and GPI anchoring to 5%
of them. Much more frequent, about 44%, was the prediction of
palmitoylation sites. Additionally, STRING analysis classified
Fig. 1 Summary of the performance of the three FASP protocols tested in this study. Total number of identified proteins, hydrophobic and membrane
proteins, and the percentage of transmembrane, peripheral, and lipid-anchored (GPI- and others) proteins are shown. ND, not-delipidated; D, delipidated.
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67% of proteins as constituents of protein complexes. These
findings are intriguing, because both such post-translational
modification and protein–protein interactions are likely to
determine a – possibly reversible – association with the
membrane MD of otherwise soluble proteins, allowing for their
dynamic binding to microdomains.39 After applying these tools
for the prediction of – direct or indirect – membrane interac-
tions, only 79 proteins (9.8%) were left out.
These results are in good agreement with a recently published
work, concerning chicken inner ear membrane MD proteomics.37
Mass spectrometry of MD fractions identified over 600 putative raft
proteins, and most of them were predicted as membrane-
associated and involved in traﬃcking and metabolism.
Very few other papers broached tissue MD proteomics. In
particular, a study by Yu et al. adopted a ‘‘tube-gel’’ protein
digestion label-free shotgun proteomic strategy to quantify raft
proteins in the neonatal mouse brain – about 200 raft proteins
were identified from a single sample, thus defining a core proteome
qualitatively quite similar to ours and previous ones.37,40,41
This highlights the common modularity features of MD, as a
quite stable structure that plays a comparable role in diﬀerent
settings.40 In fact, membrane MD, on the one hand, are highly
dynamic, with protein (and lipid) components shuttling rapidly
between raft and non-raft membranes, and on the other hand,
present a fixed and common proteomic core, accounting for
their structural and specific characteristics.
In our previous work, we analyzed the same RCC and ANK
MD samples by a gel based method (Table 1).20 The present
optimized gel-free approach seems to be more suitable for the
study of membrane microdomains, providing a higher number
of total identified proteins (742 vs. 98 in ANK MD and 721 vs. 93
in RCC MD). It is noteworthy that more than 88% of the
proteins identified with the gel-based approach were also found
using the shotgun proteomic strategy (Fig. 2), confirming their
localization in the MD.
We assessed the tissue specificity of the MD proteome,
comparing the new list of MD proteins with the Human Protein
Atlas database (HPA)33 – a comparison with the human tissue-
specific proteomes of 32 different tissues showed a peak
matching with kidney-specific ones (Fig. 3). Moreover, 30.5%
of proteins identified in RCC MD were already detected in HPA
renal cancer tissue microarrays. It has to be stressed that
subcellular fractionation, and in particular MD purification,
greatly enhances the possibility to identify low-abundance
proteins, undetectable in the whole tissue. Several protein
classes (i.e. G proteins, RAS-related proteins, components of
the vacuolar ATPase–synthase complex, etc.) cannot indeed be
tissue specific because they are typical for the MD proteome,
regardless of their tissue localization.40
We then evaluated the diﬀerential proteome by label-free
quantification, considering proteins to be ‘‘up-’’ or ‘‘down-regulated’’
when the ratio was, respectively, higher than 1.50 and lower
than 0.67.22,26 Applying these criteria to 657 quantified protein
species, 170 (25.9%) were classified as ‘‘up’’ and 126 (19.2%) as
‘‘down’’ in RCC MD (ESI,† Table S1).
The diﬀerential proteins (‘‘up’’ and ‘‘down’’) were correlated
with subcellular localization (by LocDB) and molecular func-
tion (by Panther) (Fig. 4). The majority of ‘‘down’’ proteins were
membrane-associated (70.6%) (Fig. 4A); this result could be
Fig. 2 Venn diagram of protein species identified in RCC and ANK MD
using two diﬀerent analytical approaches. The comparison of protein
identification data obtained in the present – gel free – study and in the
previous – gel based – one is shown.20
Fig. 3 Tissue specificity analysis. The number of MD proteins matched with the human tissue specific proteomes of 32 diﬀerent tissues is shown.
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dependent on the process of de-diﬀerentiation typical for
cancer cells, which lose their tubular epithelial specialization.
In fact, among ‘‘down’’ proteins, we found aquaporin-1 (AQP1), a
water-channel that is considered a kidney diﬀerentiation marker,42
Na+/glucose co-transporters 2 and 5, involved in glucose reabsorp-
tion by proximal tubule cells, and renal dipeptidase (DPEP-1), a
zinc-dependent membrane metalloprotease.43
In contrast, the ‘‘up’’ proteins are found to be partially
membrane (42.3%) and partially cytoplasmic proteins (38.2%)
(Fig. 4A). It has to be underlined that some cytosolic proteins
may associate with the plasma membrane and MD, through
cytoskeletal components.44 Several cytoskeleton associated-proteins,
such as ezrin, radixin and moesin, members of the ezrin–radixin–
moesin (ERM) family, involved in cancer progression,45 are in fact
increased in RCC MD. Interestingly, focusing on post-translational
modifications, the predicted palmitoylation sites appeared nearly
doubled (from 42.5 to 71%) among ‘‘up’’, compared to ‘‘down’’
proteins. It is tempting to speculate that this behavior is driven
by a modification of the RCC MD lipid composition, thus
allowing cancer cells to deliver new proteins, perhaps involved
in aberrant signaling events, towards MD. The elucidation of
this hypothesis deserves further investigation.
By analyzing this list of proteins using Panther, an on-line
tool for the classification of genes according to the Gene
ontology classes, we obtained the picture shown in Fig. 4B.
From a functional point of view, the presence of neoplasm
seems to increase some peculiar protein classes involved in
signaling and adhesion, typical MD-associated processes. In
fact, G proteins, structural, and binding proteins (e.g., flotillins,
tubulins, annexins, and caveolins), were more abundant in RCC
MD, compared to ANK.
It has to be underlined that most of diﬀerential proteins in
our previous gel-based study were confirmed here, after label
free quantification, for example, Basigin, DPEP1, AQP1, and
caveolin-1 (ESI,† Table S1). This result may indeed represent a
preliminary validation.
Validation of diﬀerential RCC MD protein content by
immunoblotting analysis
Relative quantification results obtained by the label-free
approach were verified by immunoblotting of three diﬀerential
proteins, carbonic anhydrase 2 (CA2), annexin A2 (ANXA2), and
aminopeptidase N (CD13), comparing the signal intensity
in diﬀerent subcellular fractions prepared from ANK and RCC
(Fig. 5).
The choice of these three proteins was firstly based on their
significantly high or low RCC/ANK ratio (CA2, 2.54; ANXA2,
1.97; CD13, 0.37) obtained after label-free quantification. Secondly,
ANXA2 and CD13 were already reported as MD associated, and
listed as High Confidence Raft Proteins in the RaftProt data-
base.38 On the other hand, CA2 is a typical cytosolic enzyme,
responsible for more than 95% of the total kidney carbonic
anhydrase activity46 and it is not usually described as a MD
bound protein.
WB results regarding ANXA2 confirmed label-free quantifi-
cation, being up-regulated in RCC samples, compared to ANK.
This diﬀerence is higher at the MD level than in whole lysates,
suggesting the occurrence of an altered subcellular localization
Fig. 4 Subcellular localization and molecular functions of the RCC diﬀerential proteins, classified into ‘‘UP’’ and ‘‘DOWN’’. (A) Pie charts representing the
cellular localization of the diﬀerential proteins. (B) Histogram representation of the percentage of diﬀerential proteins in main molecular functions.
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in the RCC tissue. ANXA2 is actually considered a marker of
several cancer cells (reviewed in ref. 47), and its overexpression
in RCC has already been reported.48 Its key role in the organi-
zation of lipid raft signaling domains by binding to membrane
phospholipids, under physiological conditions, was also described.49
A very recent paper50 outlines the regulatory role of ANXA2 in
RCC cell motility and the change in ANXA2 localization from
cytoplasm to membranes in the RCC tissue (by immunohisto-
chemistry), supporting our findings.
Aminopeptidase N is a transmembrane zinc-dependent ecto-
enzyme, expressed by various tissues, including the kidney.51
Besides its peptidase activity, it is physiologically involved in
endocytosis and signaling.52 CD13 is down-regulated in RCC
MD, as determined by label-free analysis; accordingly, its signal
was undetectable in RCC subfractions, while highly enriched
in ANK MD, compared to the homogenate and total plasma
membrane fractions. Although this protein is usually reported
as up-regulated in many cancers, such as mesenchymal tumors,
breast, ovarian and colon cancer (reviewed in ref. 53 and 54), some
studies performed on RCC tissues showed a reduction of CD13
levels, compared to ANK, both by immunohistochemistry55 and
by the measure of its surface enzymatic activity.56
CA2 appeared more abundant in all RCC subcellular frac-
tions, and its signal was particularly and specifically strong at the
RCC MD level, while undetectable in the corresponding ANK
lane, confirming once again the data obtained by label-free
quantification. These data suggest a possible tumor-dependent
mis-localization of CA2 in RCC MD. Interestingly, an increased
expression of CA2 has been reported in the neovessel endo-
thelium of several tumors, such as melanoma and esophageal,
renal, and lung cancer, but not in the corresponding healthy
vascular cells.57 Since we prepared fractions from whole RCC
tissue, the signal intensity detected inMDmay indeed be derived
from tumoral neovessels.
Overall, the validation of these three proteins further supports
the potency of label-free MS approach.
Conclusions
In conclusion, our results show the importance of setting up a
specific protocol for the proteomic analysis of membrane proteins,
according to the diﬀerent molecular features of the sample. More-
over, our data confirm that the sensitivity of proteomic profiling
can be significantly enhanced by focusing on highly enriched
subcellular fractions, such asMD. The optimization of all analytical
steps, from sample pre-fractionation and preparation to the MS
analysis and label-free quantification, provided us with a large
panel of diﬀerential RCC MD proteins, among which tumor
biomarkers may be looked for.
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